High Level Of EGFR Expression In Lung Cancer Is A Predictor For Improved Survival With Cetuximab Plus Chemotherapy
Editor's ChoiceMain Category: Lung Cancer
Also Included In: Respiratory / Asthma; Cancer / Oncology
Article Date: 04 Jul 2011 - 16:00 PDT
'High Level Of EGFR Expression In Lung Cancer Is A Predictor For Improved Survival With Cetuximab Plus Chemotherapy'
| Patient / Public: | ![]() |
3 (1 votes) |
| Healthcare Prof: | ![]() |
3.5 (2 votes) |
| Article opinions: | 1 posts |
A high level of epidermal growth factor receptor (EGFR) expression in non-small cell lung cancer is a good predictor for increased survival with cetuximab added to first-line chemotherapy, according to a major study reported at the World Conference on Lung Cancer (4 July; Amsterdam, The Netherlands).
The phase III FLEX study has previously shown that adding cetuximab to first-line, platinum-based chemotherapy significantly improves overall survival in patients with EGFR-expressing advanced non-small cell lung cancer. Researchers have now analysed the results further by looking at the association between EGFR expression in patients' tumours and their clinical outcome. They assessed the proportion of tumour cells expressing EGFR and the intensity of staining using immunohistochemistry.
Results from 1121 of the patients taking part in the FLEX study showed that 31% had high tumour EGFR expression (defined as > 200 on a scale of 0-300). Overall survival was significantly prolonged when cetuximab, a monoclonal antibody directed against EGFR, was added to chemotherapy in this group, compared to patients treated with chemotherapy alone (median 12.0 vs 9.6 months; hazard ratio 0.73; p=0.011). In contrast, there was no survival benefit with cetuximab for patients with low EGFR expression (< 200).
One-year survival was 50% in patients with high EGFR expression treated with cetuximab plus chemotherapy, compared to 37% in those given chemotherapy alone. Two-year survival was also higher (24% vs 15%).
"This new analysis of the FLEX study has allowed us to identify which patients with non-small cell lung cancer are most likely to benefit from treatment with cetuximab in the first-line setting," said Robert Pirker, professor of medicine at the Medical University of Vienna, Austria, and lead investigator of the study.
"This is the first trial to show that EGFR is a disease-related biomarker that can be used to tailor cetuximab treatment to patients most likely to derive a clinically meaningful benefit," he said, adding that immunohistochemistry is a simple and established analytical method that is widely available in pathology departments.
A treatment interaction test assessing the difference in the hazard ratios for overall survival between patients with high and low expression of EGFR was significant (p=0.044).
Written by Susan Mayor PhD
Susan Mayor PhD, freelance medical journalist, London
Reference
Pirker R, Paz Ares L, Eberhardt W et al. Epidermal growth factor receptor (EGFR) expression as a predictor of survival for first-line chemotherapy plus cetuximab in FLEX study patients with advanced non-small cell lung cancer (NSCLC). WCLC 2011; abstract 1557
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
MLA
26 May. 2012. <http://www.medicalnewstoday.com/articles/230388.php>
APA
http://www.medicalnewstoday.com/articles/230388.php.
Please note: If no author information is provided, the source is cited instead.
Visitor Opinions (latest shown first)
The molecular pathology of cancer
posted by Gregory D. Pawelski on 26 Jul 2011 at 11:35 pmThe cell-block technique is useful for special stains and immunohistochemistry (IHC) and can give morphological (structural) details by preserving (in paraffin wax) the architectural patterns. However, when it comes to drug selection, investigators can only measure those analytes (substance or chemical constituent) in paraffin wax that they know to measure. If you are not aware of and capable of measuring a biologically relevant event, you cannot seek to detect it. The cell-lines in paraffin-embedded tissue can change over time. These proliferating populations of cells are biologically distinct in their behavior from "fresh" live cells that comprise human tumors.
Tissue that is frozen, miniced, fixed, formalin-fixed or paraffin-embedded (cell-lines) have always played and continue to play an important role in drug screening and drug development. The problem is that cell-lines do not predict for disease or patient specific drug effects (drug selection). If you can kill lung cancer cell-lines with a given drug, it doesn't tell you anything about how the drug will work in real-world, clinical lung cancer (real-world conditions). But they can learn certain things about general drug biology through the study of cell-lines. As a general rule, studies from established cell-lines, tumor cells are cultured and manipilated so they continue to divide. But this is not reflective of the behavior of the fresh tumor samples (live samples derived from tumors) in primary culture, much less in the patient.
When cells are pre-cultured in monolayers, the assay endpoint is detachment of cells from the surface of the culture plates, which corrlates with with loss of viability. However, when monolayer assays are testing a subcultured cell population, studies by the NCI Navy medical oncology branch did not find that monolayer assays performed on pre-cultured, pre-amplified tumor cells clearly gave clinically relevant results. Studies by Teicher and Kerbel in mouse tumors showed that in vitro drug activity correlated with in vivo drug activity when tumors were tested in vitro as three dimensional clusters, but not when they were tested in two dimensional monolayers.
In a nutshell, cancer cells utilize cross talk and redundancy to circumvent therapies. They back up, zig-zag and move in reverse, regardless of what the sign posts say. Using genomic signatures to predict response is like saying that Dr. Seuss and Shakespeare are truly the same because they use the same words. The building blocks of human biology are carefully construed into the complexities that we recognize as human beings. However appealing gene profiling may appear to those engaged in this field it will be years, perhaps decades, before these profiles can approximate the vagaries of human
cancer.
Add Your Opinion On This Article
'High Level Of EGFR Expression In Lung Cancer Is A Predictor For Improved Survival With Cetuximab Plus Chemotherapy'Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





